(Q37832967)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21274535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

review article

1 reference

title

Contribution of the immune system to the chemotherapeutic response (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21274535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21274535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Anna K. Nowak

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21274535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Richard A Lake

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21274535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

language of work or name

1 reference

28 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21274535%20AND%20SRC:MED&resulttype=core&format=json

Seminars in Immunopathology

21 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21274535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21274535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21274535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

353-367

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21274535%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00281-011-0246-z

21 January 2020

exact match

0 references

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Cancer despite immunosurveillance: immunoselection and immunosubversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Immune surveillance of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Innate immune induction of the adaptive immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Immune-mediated dormancy: an equilibrium with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Model predicting survival in stage I melanoma based on tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

CD8+ T-cell memory in tumor immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Shaping and reshaping CD8+ T-cell memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Dendritic cells: driving the differentiation programme of T cells in viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

CD8+ T Cell Effector Mechanisms in Resistance to Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Chemokines and cell migration in secondary lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Antigen presentation to CD8+ T cells: cross-priming in infectious diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Development and maturation of secondary lymphoid tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

The generation and modulation of antigen-specific memory CD8 T cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Signals required for programming effector and memory development by CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Dendritic Cell Function in Vivo during the Steady State: A Role in Peripheral Tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Uncoupling of proliferative potential and gain of effector function by CD8(+) T cells responding to self-antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Peripheral tolerance of CD8 T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Cancer immunotherapy by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Tuning microenvironments: induction of regulatory T cells by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Immunogenic anti-cancer chemotherapy as an emerging concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Chemotherapy and radiotherapy: cryptic anticancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Immunogenic death of colon cancer cells treated with oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Uric acid promotes tumor immune rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Molecular identification of a danger signal that alerts the immune system to dying cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Molecular mechanisms of regulatory T cell development and suppressive function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Therapeutic targeting of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Features of responding T cells in cancer and chronic infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00281-011-0246-Z

21 January 2018

12 December 2020

Modification of tumor regression by immunologic means

1 reference

12 December 2020

Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC

1 reference

12 December 2020

Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma

1 reference

12 December 2020

High Number of Intraepithelial CD8+Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer

1 reference

12 December 2020

Progressor but not regressor skin tumours inhibit Langerhans' cell migration from epidermis to local lymph nodes

1 reference

12 December 2020

Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide

1 reference

12 December 2020

Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response

1 reference

12 December 2020

Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice.

1 reference

12 December 2020

Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.

1 reference

12 December 2020

Tumor antigens are constitutively presented in the draining lymph nodes

1 reference

12 December 2020

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer

1 reference

12 December 2020

Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells

1 reference

12 December 2020

Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide

1 reference

12 December 2020

Antitumor Effects of Kethoxal-Bis(Thiosemicarbazone) and 6-Mercaptopurine in Neonatally Thymeetomized Mice

1 reference

12 December 2020

Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity

1 reference

12 December 2020

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

1 reference

12 December 2020

Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients

1 reference

12 December 2020

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma

1 reference

12 December 2020

Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse

1 reference

12 December 2020

Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy

1 reference

12 December 2020

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

1 reference

12 December 2020

Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients

1 reference

12 December 2020

Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells

1 reference

12 December 2020

Efficient Treg depletion induces T-cell infiltration and rejection of large tumors

1 reference

12 December 2020

CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection

1 reference

12 December 2020

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide

1 reference

12 December 2020

Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer

1 reference

12 December 2020

Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer

1 reference

12 December 2020

Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression

1 reference

12 December 2020

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

1 reference

12 December 2020

Increase of regulatory T cells in the peripheral blood of cancer patients.

1 reference

12 December 2020

Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL

1 reference

12 December 2020

Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors

1 reference

12 December 2020

Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors

1 reference

12 December 2020

CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression

1 reference

12 December 2020

10.1007/S00281-011-0246-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21274535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference